Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) finished Friday with a subtraction of -$0.15 to close at $0.55, a downside of -21.98 percent. An average of 791,840 shares of common stock have been traded in the last five days. There was a fall of -$0.2667 in the past week, and it reached a new high 8 times over the past 12 months. The last 20 days have seen an average of 324,465 shares traded, while the 50-day average volume stands at 515,180.
TNXP stock has decreased by -42.02% in the last month. The company shares reached their 1-month lowest point of $0.4925 on 09/29/23. With the stock rallying to its 52-week high on 01/13/23, shares of the company touched a low of $0.68 and a high of $9.81 in 52 weeks. It has reached a new high 8 times so far this year and lost -77.63% or -$1.8912 in price. In spite of this, the price is down -94.45% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Tonix Pharmaceuticals Holding Corp (TNXP) stock’s beta is 2.23. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.04.
Financial Health
The quick ratio of Tonix Pharmaceuticals Holding Corp for the three months ended June 29 was 2.04, and the current ratio was 2.78, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.01 and a total debt to equity ratio of 0.01 for the quarter ending June 29.
Earnings Surprise
The company posted a net income of -$28.36 million in the quarter, while revenues were grew 6.84%. The analyst consensus anticipated Tonix Pharmaceuticals Holding Corp’s latest quarter earnings to come in at -$2.75 per share, but it turned out to be -$2.68, a 2.50% surprise. Shareholders own equity worth $17.76 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Tonix Pharmaceuticals Holding Corp (TNXP) price momentum. RSI 9-day as of the close on 29 September was 10.27%, suggesting the stock is oversold, with historical volatility in this time frame at 114.35%.
As of today, TNXP’s price is $0.7122 -32.86% or -$0.2667 from its 5-day moving average. TNXP is currently trading -43.61% lower than its 20-day SMA and -82.87% lower than its 100-day SMA. However, the stock’s current price level is -67.75% below the SMA50 and -78.20% below the SMA200.
The stochastic %K and %D were 10.36% and 11.90%, respectively, and the average true range (ATR) was 0.0690. With the 14-day stochastic at 12.00% and the average true range at 0.0650, the RSI (14) stands at 16.41%. The stock has reached -0.1047 on the 9-day MACD Oscillator while the 14-day reading was at -0.1517.
Analyst Ratings
Noble Capital Markets launched coverage on Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) in its analyst report released on April 18, 2022. The firm assigned the stock an Outperform rating. The consensus rating for Tonix Pharmaceuticals Holding Corp (TNXP) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TNXP, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is TNXP’s price target for the next 12 months?
Analysts predict a range of price targets between $8.00 and $10.00, with a median target of $8.00. Taking a look at these predictions, the average price target given by analysts for Tonix Pharmaceuticals Holding Corp (TNXP) stock is $8.67.
